Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline

被引:40
作者
Cirioni, O [1 ]
Giacometti, A [1 ]
Barchiesi, F [1 ]
Scalise, G [1 ]
机构
[1] Univ Ancona, Inst Infect Dis & Publ Hlth, Ancona, Italy
关键词
D O I
10.1093/jac/46.4.577
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The in vitro activity of lactoferrins alone and in combination with clarithromycin, minocycline and pyrimethamine was investigated against three clinical isolates of Pneumocystis carinii. Susceptibility was tested by inoculating isolates on to cell monolayers and determining the parasite count after 72 h incubation at 37 degreesC. The culture medium was supplemented with serial dilutions of each agent. At 20 mg/L, bovine lactoferrin, the most active agent, suppressed the growth of cystic and trophic forms by >60%. Human lactoferrin, at the same concentration, suppressed the growth of cystic and trophic forms by >50%. Lactoferrins at 20 mg/L combined with clarithromycin 4 mg/L had high anti-P. carinii activity, with a >90% decrease in cystic and trophic form counts. Our study suggests that lactoferrins may inhibit P. carinii growth in vitro and act synergically with other clinically used compounds. These findings lend experimental support to the use of iron-chelating agents in the therapy of pneumocystis infections.
引用
收藏
页码:577 / 582
页数:6
相关论文
共 32 条
[21]   The structure of the antimicrobial active center of lactoferricin B bound to sodium dodecyl sulfate micelles [J].
Schibli, DJ ;
Hwang, PM ;
Vogel, HJ .
FEBS LETTERS, 1999, 446 (2-3) :213-217
[22]  
Sepkowitz KA, 1993, CLIN INFECT DIS S2, V17, P416
[23]  
SOUKKA T, 1992, FEMS MICROBIOL LETT, V69, P223
[24]   CLINDAMYCIN PRIMAQUINE VERSUS TRIMETHOPRIM-SULFAMETHOXAZOLE AS PRIMARY THERAPY FOR PNEUMOCYSTIS-CARINII PNEUMONIA IN AIDS - A RANDOMIZED, DOUBLE-BLIND PILOT TRIAL [J].
TOMA, E ;
FOURNIER, S ;
DUMONT, M ;
BOLDUC, P ;
DESCHAMPS, H .
CLINICAL INFECTIOUS DISEASES, 1993, 17 (02) :178-184
[25]  
Vorland LH, 1999, SCAND J INFECT DIS, V31, P179, DOI 10.1080/003655499750006245
[26]  
Vorland LH, 1999, SCAND J INFECT DIS, V31, P173, DOI 10.1080/003655499750006236
[27]   Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: Analysis of drug interactions and efficacies [J].
Walzer, PD ;
Runck, J ;
Orr, S ;
Foy, J ;
Steele, P ;
White, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :242-250
[28]   Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs [J].
Walzer, PD ;
Runck, J ;
Steele, P ;
White, M ;
Linke, MJ ;
Sidman, CL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :251-258
[29]   IRON CHELATORS AS THERAPEUTIC AGENTS AGAINST PNEUMOCYSTIS-CARINII [J].
WEINBERG, GA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (05) :997-1003
[30]  
Weinberg GA, 1996, PEDIATR RES, V39, P1112